PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 17221836

When behavioral assessment detects frontotemporal dementia and cognitive testing does not: data from the Frontal Behavioral Inventory.

Graziella Milan·Alessandro Iavarone·Elisa Lorè·Sara Vitaliano·Francesco Lamenza·Paolo Sorrentino·Alfredo Postiglione
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Behavioral SymptomsCaregiversCognition DisordersDementiaHumansPsychiatric Status Rating ScalesSensitivity and SpecificitySurveys and QuestionnairesComparative StudyJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Graziella Milan, Alessandro Iavarone, Elisa Lorè, Sara Vitaliano, Francesco Lamenza, Paolo Sorrentino, Alfredo Postiglione. 2007. When behavioral assessment detects frontotemporal dementia and cognitive testing does not: data from the Frontal Behavioral Inventory.. https://doi.org/10.1002/gps.1697

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia.

OBJECTIVE: The objective of this study was to evaluate donepezil, an acetylcholinesterase inhibitor, in the treatment of frontotemporal dementia (FTD). METHODS: Twelve patients with FTD who received donepezil for six months were compared with 12 FTD controls on behavioral measures. RESULTS: The groups did not differ on most variables at baseline or at six months; however, the donepezil group had greater worsening on the FTD Inventory. Four treated patients had increased disinhibited or compulsive acts, which abated with discontinuation of the medication. CONCLUSION: There were no changes in global cognitive performance or dementia severity; however, a subgroup of patients with FTD can experience worsening of symptoms with donepezil.

Behavioral Symptoms↗
PubMed2006

Clinical characteristics of cortical multiple sclerosis.

There are several articles in this special issue in which authors eloquently describe neurobehavioural and cognitive complications of multiple sclerosis with relevant neuropsychological assessments and neuroimaging findings. However behavioural and cognitive presentation of multiple sclerosis remains poorly understood. Two years ago, we reported a series of patients with multiple sclerosis who presented with neurobehavioural symptoms and had neuropsychological deficits consistent with cortical dysfunction. Based on previous case reports, pathological studies of cerebral cortex in multiple sclerosis and advanced neuroimaging studies we suggested that neurobehavioural presentation of multiple sclerosis represents a new variant called "cortical multiple sclerosis". The condition is characterised by predominant or exclusive cortical pathology presenting with neurobehavioural symptoms, such as depression, amnesia or distinct cortical syndromes. Since the publication of our report, there has been further neuroimaging and neuropathological findings that further supported the above concept. In addition, observation of more patients with this condition helped us to formulate a logical approach in the detection of these patients. This article focuses on their clinical characteristics.

Behavioral Symptoms↗
PubMed2006

Cognitive dysfunction and emotional-behavioural changes in MS: the potential of positron emission tomography.

Cognitive dysfunction and emotional-behavioral changes are symptoms with increasing clinical relevance during progression of the disease. They cannot be explained by demyelination of white matter alone but clearly indicate cortical dysfunction. Positron emission tomography (PET) provides methods to assess cortical dysfunction quantitatively by measuring cerebral glucose metabolism using the tracer (18)F-2-fluoro-2-deoxy-d-glucose (FDG). The technique has been employed to study fatigue and disease progression. Microglial activation was studied by 11C-PK-11195 PET. It was found not only in active plaques but also in degenerating fibre tracks. Other tracers offer a broad spectrum of measuring local physiological functions and pathophysiological processes, but some of them are still limited to experimental animal research.

Behavioral Symptoms↗